Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Non-cash Items (2018 - 2022)

Kiora Pharmaceuticals' Non-cash Items history spans 5 years, with the latest figure at $429000.0 for Q3 2022.

  • For Q3 2022, Non-cash Items rose 113.97% year-over-year to $429000.0; the TTM value through Sep 2022 reached $429000.0, up 113.97%, while the annual FY2021 figure was $201653.0, 41.95% up from the prior year.
  • Non-cash Items reached $429000.0 in Q3 2022 per KPRX's latest filing, down from $473000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $1.4 million in Q2 2018 to a low of $96863.0 in Q3 2018.
  • Average Non-cash Items over 5 years is $285847.4, with a median of $142061.0 recorded in 2020.
  • Peak YoY movement for Non-cash Items: tumbled 92.3% in 2019, then soared 267.5% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $96863.0 in 2018, then grew by 21.34% to $117534.0 in 2019, then rose by 20.87% to $142061.0 in 2020, then surged by 41.95% to $201653.0 in 2021, then soared by 112.74% to $429000.0 in 2022.
  • Per Business Quant, the three most recent readings for KPRX's Non-cash Items are $429000.0 (Q3 2022), $473000.0 (Q2 2022), and $647000.0 (Q1 2022).